AB-PA01

AXP000223.1 · Phage therapy

Platform
phage cocktail (fixed composition)
Originator
AmpliPhi Biosciences
Sponsor
Armata Pharmaceuticals

Names

NameTypeSource
AB-PA01preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Pseudomonas aeruginosa bacteriophage (cocktail)
Replication
replicating
Route
intravenous, inhaled
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03395743Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage TherapeuticNo longer available

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38347019Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers.Scientific reports2024name in abstract: AB-PA01
PMID 32443619Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms.Viruses2020name in abstract: AB-PA01

Notes

Anti-Pseudomonas aeruginosa phage product used under emergency/compassionate access, including three lung transplant recipients (Aslam 2019, Am J Transplant 19:2631-2639) and a ventilator-associated pneumonia case given it intravenously and by inhalation; US expanded-access record NCT03395743. Distinct from the later AP-PA02.

How to cite

AB-PA01 (AXP000223.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000223.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.